Lilly Endowment Inc sells Eli Lilly shares worth nearly $75 million

Lilly Endowment Inc, a major shareholder in Eli Lilly & Co (NYSE:), has recently sold a substantial number of shares in the pharmaceutical giant. The transaction, which took place on May 24, involved the sale of 92,563 shares at an average weighted price of $809.211, resulting in a total sale value of approximately $74,902,997.

The sales occurred in multiple transactions with prices ranging from $809.00 to $809.90 per share. Following this transaction, Lilly Endowment Inc still holds a significant stake in the company, with 98,556,247 shares remaining in its possession.

The sale was disclosed in a regulatory filing with the Securities and Exchange Commission (SEC), providing transparency into the trading activities of the company’s major shareholders. Lilly Endowment Inc, which is not affiliated with any director or executive officer of Eli Lilly & Co, is known for holding a sizeable portion of the company’s stock.

Investors often monitor such sales by significant shareholders as they can sometimes provide insights into the shareholder’s view of the stock’s valuation or potential future performance. However, it’s important to note that sales by major shareholders can occur for a variety of reasons and may not necessarily reflect a negative outlook on the company.

Eli Lilly & Co, headquartered in Indianapolis, Indiana, is a leading pharmaceutical company with a range of products addressing various medical conditions. The company’s stock is traded on the New York Stock Exchange under the ticker symbol LLY, and it is a component of the S&P 500 index.

For those interested in the specifics of the transactions, the SEC filing includes a commitment from the reporting person to provide full information regarding the number of shares sold at each separate price within the provided ranges upon request.

The disclosed sale by Lilly Endowment Inc represents a notable activity in the market for Eli Lilly & Co shares, and investors will be watching to see if there are any further developments or transactions from major shareholders in the near future.

InvestingPro Insights

Eli Lilly & Co (NYSE:LLY) has been in the spotlight following significant shareholder transactions. In the context of these events, it’s worth examining some key financial metrics and analyst insights from InvestingPro to glean a deeper understanding of the company’s current market standing.

With a robust market capitalization of $727.39 billion, Eli Lilly showcases its substantial presence in the pharmaceutical industry. The company has been trading at a high earnings multiple, with a P/E ratio of 117.61, which could indicate high investor expectations for future earnings growth. However, the adjusted P/E ratio for the last twelve months as of Q1 2024 stands at a slightly lower 76.14, reflecting a somewhat moderated valuation over time.

InvestingPro Tips highlight that Eli Lilly has raised its dividend for 9 consecutive years, demonstrating a commitment to returning value to shareholders. Additionally, the company has maintained dividend payments for an impressive 54 consecutive years, reinforcing its reputation for reliability in income distribution.

Revenue growth also paints a positive picture, with a 29.76% increase over the last twelve months as of Q1 2024. This financial strength is further underscored by a substantial gross profit margin of 80.16%, indicating efficient operations and strong pricing power.

For those looking to delve deeper into Eli Lilly’s financial health and projections, InvestingPro offers a wealth of additional tips. Currently, there are 19 more InvestingPro Tips available, which can provide investors with a comprehensive analysis of the company’s performance and outlook. Interested readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking access to these valuable insights.

As investors digest the recent share sale by Lilly Endowment Inc, these InvestingPro metrics and tips could offer a broader context for understanding Eli Lilly’s financial trajectory and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.


This website uses cookies. By continuing to use this site, you accept our use of cookies.